H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

NCT01964391 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

NCT02286362 ·Status: COMPLETED

An Observational Study of Herceptin SC Safety in Breast Cancer

NCT02305628 ·Status: COMPLETED

Cardiac Safety Study in Patients With HER2 + Breast Cancer

NCT01904903 ·Status: COMPLETED ·Phase: PHASE2

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01566721 ·Status: COMPLETED ·Phase: PHASE3

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

NCT01548677 ·Status: COMPLETED ·Phase: PHASE2

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

NCT01926886 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer

NCT07166185 ·Status: RECRUITING

Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer

NCT02424682 ·Status: COMPLETED

Identification of Early Markers of Response and Resistance to Trastuzumab

NCT01834950 ·Status: COMPLETED ·Phase: NA

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

NCT02748213 ·Status: COMPLETED ·Phase: PHASE2

A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

NCT00337649 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

NCT02658461 ·Status: COMPLETED

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

NCT01301729 ·Status: COMPLETED ·Phase: PHASE4

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

NCT04109391 ·Status: COMPLETED ·Phase: PHASE3

Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients

NCT00740532 ·Status: COMPLETED

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT07047755 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

NCT00545688 ·Status: COMPLETED ·Phase: PHASE2

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

NCT01401166 ·Status: COMPLETED ·Phase: PHASE2

A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer

NCT02443467 ·Status: COMPLETED

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

NCT00381901 ·Status: COMPLETED ·Phase: PHASE3

A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients

NCT03983382 ·Status: ACTIVE_NOT_RECRUITING

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

NCT03556358 ·Status: COMPLETED ·Phase: PHASE3

A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

NCT02040935 ·Status: COMPLETED ·Phase: PHASE3

HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia

NCT05905939 ·Status: COMPLETED